Functional diversity of the <i>TP53</i> mutome revealed by saturating CRISPR mutagenesis

Julianne Funk(Philipps University of Marburg), Maria Klimovich(Philipps University of Marburg), Evangelos Pavlakis(Philipps University of Marburg), Michelle M. Neumann(Philipps University of Marburg), Daniel Drangenstein(Philipps University of Marburg), Amir Noeparast(Philipps University of Marburg), Pascal Hunold(Philipps University of Marburg), Anna Borowek(Philipps University of Marburg), Dimitrios-Ilias Balourdas(Goethe University Frankfurt), Katharina Kochhan(Philipps University of Marburg), Nastasja Merle(Philipps University of Marburg), Imke Bullwinkel(Philipps University of Marburg), Michael Wanzel(Philipps University of Marburg), Sabrina Elmshäuser(Philipps University of Marburg), Andrea Nist(Philipps University of Marburg), Tara Procida(Justus-Liebig-Universität Gießen), Marek Bartkuhn(Justus-Liebig-Universität Gießen), Katharina Humpert(Philipps University of Marburg), Marco Mernberger(Philipps University of Marburg), Rajkumar Savai(Justus-Liebig-Universität Gießen), Andreas C. Joerger(Goethe University Frankfurt), Thorsten Stiewe(Philipps University of Marburg)
bioRxiv (Cold Spring Harbor Laboratory)
March 10, 2023
Cited by 3Open Access
Full Text

Abstract

Abstract The tumor suppressor gene TP53 is the most frequently mutated gene in various cancers. Unlike other tumor suppressors, TP53 is mostly hit by missense mutations, of which more than 2,000 have been described in cancer patients. To take advantage of TP53 mutation status for personalized therapy, a deeper knowledge of the functional ramifications of specific mutations is required as evidence of the functional heterogeneity of mutant p53 proteins mounts. Here, we report on a CRISPR-based saturation mutagenesis screen of 9,225 variants expressed from the endogenous TP53 gene locus of a cancer cell. By tracking changes in the abundance of individual variants in response to specific p53-pathway stimulation, we were able to construct high-resolution functional activity maps of the TP53 mutome, covering ∼94.5% of all cancer-associated missense mutations. The results demonstrate the impact of individual mutations on tumor cell fitness with unprecedented precision and coverage, even revealing underlying mechanisms such as apoptosis. The high discriminatory power also resolves subtle loss-of-function phenotypes and highlights a subset of mutants as particularly promising targets for pharmacological reactivation. Moreover, the data offer intriguing insight into the role of aberrant splicing and nonsense-mediated mRNA decay in clearing truncated proteins due to not only nonsense, frameshift, and splice-site mutations but also missense and synonymous mutations. Surprisingly, no missense mutation provided an immediate proliferative advantage over a null mutation. Nonetheless, cells with a missense, but not null mutations, acquired pro-metastatic properties after prolonged growth in mice, emphasizing the significance of mutant p53-directed clonal evolution in the progression of tumors towards metastasis.


Related Papers

No related papers found

Powered by citation graph analysis